biologic

Omvoh

mirikizumab-mrkz

Loss of exclusivityOctober 2035projected — 12-year biologic exclusivity estimate
CompanyEli Lilly and Company

Drug detail

Brand nameOmvoh
Active ingredientmirikizumab-mrkz
Strength300MG/15ML (20MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found